VHT - Vanguard Health Care ETF

NYSEArca - Nasdaq Real Time Price. Currency in USD
173.63
-0.04 (-0.02%)
As of 10:32AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close173.67
Open173.83
Bid173.78 x 1000
Ask173.80 x 800
Day's Range173.12 - 173.84
52 Week Range145.25 - 173.84
Volume120,206
Avg. Volume144,928
Net Assets8.96B
NAV168.63
PE Ratio (TTM)71.90
Yield1.25%
YTD Return10.09%
Beta (3y)1.04
Expense Ratio (net)0.10%
Inception Date2004-01-26
Trade prices are not sourced from all markets
  • ETF Trends12 days ago

    Investors Flocked to Healthcare ETFs in July

    With the healthcare sector recently outperforming technology, investors have been embracing healthcare exchange traded funds. The Health Care Select Sector SPDR (XLV) is the largest healthcare ETF by assets. XLV allocates about two-thirds of its combined weight to pharmaceuticals and biotechnology stocks.

  • 5 ETFs for a Historically Low August
    InvestorPlace15 days ago

    5 ETFs for a Historically Low August

    The month of August started off on a shaky note for Wall Street with Fed imposed rising rate concerns and severity in the U.S.-Sino trade relations coming to the forefront.The Trump administration is reportedly considering a hike in tariffs from 10% to 20% on $200 billion worth of Chinese goods, after a 25% tariff announcement on $50 billion worth of goods.Source: Shutterstock

  • 5 ETFs for a Historically Low August
    Zacks18 days ago

    5 ETFs for a Historically Low August

    Trade war talks and faster Fed rate hike concerns may mess with Wall Street in August. These five picks may save investors.

  • Investopedialast month

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • Business Wire2 months ago

    E*TRADE Adds Several of Today’s Most Popular ETFs to Commission-Free ETF Lineup

    E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr

  • 3 Top Index Funds to Keep You in the Investing Game
    Motley Fool3 months ago

    3 Top Index Funds to Keep You in the Investing Game

    A few great places to park your cash when you'd rather not direct it toward a single stock.

  • A Overview of Merck’s Diabetes Products in 1Q18
    Market Realist3 months ago

    A Overview of Merck’s Diabetes Products in 1Q18

    Merck’s (MRK) diabetes products include blockbuster drugs Januvia (sitagliptin) and Janumet (sitagliptin and metformin hydrochloride). Both drugs are used to control blood sugar levels in patients with diabetes.

  • Allergan’s US General Medicines Segment in 1Q18
    Market Realist3 months ago

    Allergan’s US General Medicines Segment in 1Q18

    Allergan’s (AGN) US General Medicines segment includes revenues from the US sales of its central nervous system products, women’s health products, gastrointestinal products, anti-infective products, and diversified brands.

  • Mounting Evidence of Inflation Firming Up
    Market Realist4 months ago

    Mounting Evidence of Inflation Firming Up

    The U.S. Commerce Department reported retail sales fell in February for the third month in a row, while the University of Michigan Consumer Sentiment Index4 jumped to a 14-year high and the Conference Board Consumer Confidence Index5 hovers near 17-year highs. This suggests that while times are good for most people, they have little desire to spend more in an economic expansion that is one of the longest on record. Households may save their gains from the Trump tax cuts, rather than spend in the economy, as the Commerce Department reports the savings rate ticked higher in February.

  • Merck’s 1Q18 Estimates: Revenues Expected to Increase
    Market Realist4 months ago

    Merck’s 1Q18 Estimates: Revenues Expected to Increase

    Analysts expect Merck & Co.’s (MRK) revenues to increase ~7.1% to $10.1 billion in 1Q18, compared to revenues of $9.4 billion in 1Q17. Revenues for 1Q18 are expected to have a positive impact on growth in operating revenues and a favorable impact from foreign exchange.

  • Allergan Reports 1Q18 Earnings, Revenue Growth
    Market Realist4 months ago

    Allergan Reports 1Q18 Earnings, Revenue Growth

    Allergan (AGN) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues today. It reported EPS of $3.74 on revenues of $3.7 billion, compared to EPS of $3.36 on revenues of $3.6 billion in 1Q18.

  • What Analysts Expect for Pfizer in 1Q18
    Market Realist4 months ago

    What Analysts Expect for Pfizer in 1Q18

    Pfizer (PFE) is one of the largest pharmaceutical companies by revenue. Pfizer (PFE) is set to release its 1Q18 earnings on May 1, 2018. Wall Street analysts estimate Pfizer will report earnings per share (or EPS) of $0.74 on revenues of $13.1 billion for 1Q18.

  • How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
    Market Realist4 months ago

    How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18

    About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.

  • InvestorPlace5 months ago

    The 3 Best Low-Cost Retirement Funds

    When it comes to assessing the cost of a retirement mutual fund or exchange-traded fund, most investors simply look at the absolute value of the expense ratio. The lower the expense ratio, they figure, the better. For some ETFs and funds, the definition of low-cost retirement funds is relative.

  • Analysts’ Recommendations for Johnson & Johnson in March 2018
    Market Realist5 months ago

    Analysts’ Recommendations for Johnson & Johnson in March 2018

    Analyzing Johnson & Johnson’s Stock and Valuations in March 2018

  • How Merck’s Quarterly Revenues Trended in 2017
    Market Realist5 months ago

    How Merck’s Quarterly Revenues Trended in 2017

    What Analysts Recommend for Merck in March 2018

  • Must-Know Developments for Ionis Pharmaceuticals in 2018
    Market Realist5 months ago

    Must-Know Developments for Ionis Pharmaceuticals in 2018

    How Ionis Pharmaceuticals Is Positioned in 2018

  • How to Invest in Healthcare Stocks the Easy Way
    Motley Fool5 months ago

    How to Invest in Healthcare Stocks the Easy Way

    Here are several smart ways to invest in the companies that keep people healthy.

  • Assessing Pfizer’s 4Q17 Quarterly Revenue Trend
    Market Realist5 months ago

    Assessing Pfizer’s 4Q17 Quarterly Revenue Trend

    An Overview of Pfizer's 4Q17: What Lies Ahead?

  • Changes in Johnson & Johnson’s Profit Margins in 4Q17
    Market Realist5 months ago

    Changes in Johnson & Johnson’s Profit Margins in 4Q17

    Changes in Johnson & Johnson's Valuation in February 2018

  • What’s ahead for Abbott Laboratories’ Medical Device Unit?
    Market Realist6 months ago

    What’s ahead for Abbott Laboratories’ Medical Device Unit?

    What's Next for Abbott Laboratories after a Stellar 2017?

  • Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings
    Market Realist7 months ago

    Analysts’ Estimates for Eli Lilly’s 4Q17 Earnings

    A Preview of Eli Lilly’s 4Q17 Earnings Release on January 31A look at Eli Lilly & Co.

  • What Are Pfizer’s Positive Growth Contributors?
    Market Realist7 months ago

    What Are Pfizer’s Positive Growth Contributors?

    Pfizer’s (PFE) business is classified into two business segments—the Innovative Health segment and Essential Health segment. The products that are expected to contribute towards Pfizer’s revenue growth include Eliquis, Sulperazon, Lipitor, Chantix/Champix, Lyrica IH, Xalkori, Xeljanz, Celebrex, Medrol, and Xtandi. The above chart compares the revenues for Pfizer’s key growth contributors in the past few quarters.

  • Investopedia7 months ago

    Top 3 Healthcare ETFs for 2018

    The solid performance of the healthcare market in 2017 has created investment opportunities. These ETFs are poised to take advantage.

  • What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?
    Market Realist7 months ago

    What Led to Arrowhead Pharmaceuticals’ Revenue Surge in 2017?

    Arrowhead Pharmaceuticals: A Promising Drug Pipeline